|
|
|
|
Vol. 9, Issue 7, 1903-1918, July 1998
during Bone Remodeling
§
and
*Departments of Growth and Development,
Bone remodeling depends on the spatial and temporal coupling of
bone formation by osteoblasts and bone resorption by osteoclasts; however, the molecular basis of these inductive interactions is unknown. We have previously shown that osteoblastic overexpression of
TGF-
Biochemistry
and Biophysics,
¶Anatomy, and
Pediatrics,
§Programs in Cell Biology and Developmental Biology,
University of California at San Francisco, San Francisco,
California 94143
2 in transgenic mice deregulates bone remodeling and leads to an
age-dependent loss of bone mass that resembles high-turnover osteoporosis in humans. This phenotype implicates TGF-
2 as a physiological regulator of bone remodeling and raises the question of
how this single secreted factor regulates the functions of osteoblasts
and osteoclasts and coordinates their opposing activities in vivo. To
gain insight into the physiological role of TGF-
in bone remodeling,
we have now characterized the responses of osteoblasts to TGF-
in
these transgenic mice. We took advantage of the ability of alendronate
to specifically inhibit bone resorption, the lack of osteoclast
activity in c-fos
/
mice, and a new
transgenic mouse line that expresses a dominant-negative form of the
type II TGF-
receptor in osteoblasts. Our results show that TGF-
directly increases the steady-state rate of osteoblastic differentiation from osteoprogenitor cell to terminally differentiated osteocyte and thereby increases the final density of osteocytes embedded within bone matrix. Mice overexpressing TGF-
2 also have increased rates of bone matrix formation; however, this activity does
not result from a direct effect of TGF-
on osteoblasts, but is more
likely a homeostatic response to the increase in bone resorption caused
by TGF-
. Lastly, we find that osteoclastic activity contributes to
the TGF-
-induced increase in osteoblast differentiation at sites of
bone resorption. These results suggest that TGF-
is a
physiological regulator of osteoblast differentiation and acts as a
central component of the coupling of bone formation to resorption
during bone remodeling.
This article has been cited by other articles:
![]() |
A. L. M. Sutton, X. Zhang, D. R. Dowd, Y. P. Kharode, B. S. Komm, and P. N. MacDonald Semaphorin 3B Is a 1,25-Dihydroxyvitamin D3-Induced Gene in Osteoblasts that Promotes Osteoclastogenesis and Induces Osteopenia in Mice Mol. Endocrinol., June 1, 2008; 22(6): 1370 - 1381. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Janssens, P. ten Dijke, S. Janssens, and W. Van Hul Transforming Growth Factor-{beta}1 to the Bone Endocr. Rev., October 1, 2005; 26(6): 743 - 774. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. V. Komarova Mathematical Model of Paracrine Interactions between Osteoclasts and Osteoblasts Predicts Anabolic Action of Parathyroid Hormone on Bone Endocrinology, August 1, 2005; 146(8): 3589 - 3595. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Valverde-Franco, H. Liu, D. Davidson, S. Chai, H. Valderrama-Carvajal, D. Goltzman, D. M. Ornitz, and J. E. Henderson Defective bone mineralization and osteopenia in young adult FGFR3-/- mice Hum. Mol. Genet., February 1, 2004; 13(3): 271 - 284. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Karsdal, P. Hjorth, K. Henriksen, T. Kirkegaard, K. L. Nielsen, H. Lou, J.-M. Delaisse, and N. T. Foged Transforming Growth Factor-{beta} Controls Human Osteoclastogenesis through the p38 MAPK and Regulation of RANK Expression J. Biol. Chem., November 7, 2003; 278(45): 44975 - 44987. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Chiusaroli, A. Maier, M. C. Knight, M. Byrne, L. M. Calvi, R. Baron, S. M. Krane, and E. Schipani Collagenase Cleavage of Type I Collagen Is Essential for Both Basal and Parathyroid Hormone (PTH)/PTH-Related Peptide Receptor-Induced Osteoclast Activation and Has Differential Effects on Discrete Bone Compartments Endocrinology, September 1, 2003; 144(9): 4106 - 4116. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. W. A. McGowan, H. MacPherson, K. Janssens, W. Van Hul, J. C. Frith, W. D. Fraser, S. H. Ralston, and M. H. Helfrich A Mutation Affecting the Latency-Associated Peptide of TGF{beta}1 in Camurati-Engelmann Disease Enhances Osteoclast Formation in Vitro J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3321 - 3326. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Chagraoui, M. Tulliez, T. Smayra, E. Komura, S. Giraudier, T. Yun, N. Lassau, W. Vainchenker, and F. Wendling Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO Blood, April 15, 2003; 101(8): 2983 - 2989. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Karsdal, L. Larsen, M. T. Engsig, H. Lou, M. Ferreras, A. Lochter, J.-M. Delaisse, and N. T. Foged Matrix Metalloproteinase-dependent Activation of Latent Transforming Growth Factor-beta Controls the Conversion of Osteoblasts into Osteocytes by Blocking Osteoblast Apoptosis J. Biol. Chem., November 8, 2002; 277(46): 44061 - 44067. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Szweras, D. Liu, E. A. Partridge, J. Pawling, B. Sukhu, C. Clokie, W. Jahnen-Dechent, H. C. Tenenbaum, C. J. Swallow, M. D. Grynpas, et al. alpha 2-HS Glycoprotein/Fetuin, a Transforming Growth Factor-beta /Bone Morphogenetic Protein Antagonist, Regulates Postnatal Bone Growth and Remodeling J. Biol. Chem., May 24, 2002; 277(22): 19991 - 19997. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-F. Lai and S.-L. Cheng Signal Transductions Induced by Bone Morphogenetic Protein-2 and Transforming Growth Factor-beta in Normal Human Osteoblastic Cells J. Biol. Chem., May 3, 2002; 277(18): 15514 - 15522. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kaneda, T. Nojima, M. Nakagawa, A. Ogasawara, H. Kaneko, T. Sato, H. Mano, M. Kumegawa, and Y. Hakeda Endogenous Production of TGF-{beta} Is Essential for Osteoclastogenesis Induced by a Combination of Receptor Activator of NF-{kappa}B Ligand and Macrophage-Colony- Stimulating Factor J. Immunol., October 15, 2000; 165(8): 4254 - 4263. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Nguyen and J. Pollard Transforming growth factor beta3 induces cell death during the first stage of mammary gland involution Development, January 7, 2000; 127(14): 3107 - 3118. [Abstract] [PDF] |
||||
![]() |
G. Karsenty The genetic transformation of bone biology Genes & Dev., December 1, 1999; 13(23): 3037 - 3051. [Full Text] |
||||
![]() |
T. E. Hefferan, G. G. Reinholz, D. J. Rickard, S. A. Johnsen, K. M. Waters, M. Subramaniam, and T. C. Spelsberg Overexpression of a Nuclear Protein, TIEG, Mimics Transforming Growth Factor-beta Action in Human Osteoblast Cells J. Biol. Chem., June 30, 2000; 275(27): 20255 - 20259. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Saito, A. Kinoshita, K.-i. Yoshiura, Y. Makita, K. Wakui, K. Honke, N. Niikawa, and N. Taniguchi Domain-specific Mutations of a Transforming Growth Factor (TGF)-beta 1 Latency-associated Peptide Cause Camurati-Engelmann Disease Because of the Formation of a Constitutively Active Form of TGF-beta 1 J. Biol. Chem., April 6, 2001; 276(15): 11469 - 11472. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-F. Lai, X. Feng, R. Nishimura, S. L. Teitelbaum, L. V. Avioli, F. P. Ross, and S.-L. Cheng Transforming Growth Factor-beta Up-regulates the beta 5 Integrin Subunit Expression via Sp1 and Smad Signaling J. Biol. Chem., November 10, 2000; 275(46): 36400 - 36406. [Abstract] [Full Text] [PDF] |
||||